ACYCLOVIR

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category Free-form
UNII X4HES1O11F
EPA CompTox DTXSID1022556

Structure

InChI Key MKUXAQIIEYXACX-UHFFFAOYSA-N
Smiles Nc1nc2c(ncn2COCCO)c(=O)[nH]1
InChI
InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

Physicochemical Descriptors

Property Name Value
Molecular Formula C8H11N5O3
Molecular Weight 225.21
AlogP -0.92
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 4.0
Polar Surface Area 119.31
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 16.0

Metabolites Network

visNetwork

Bioactivity

Mechanism of Action Action Reference
Human herpesvirus 1 DNA polymerase inhibitor INHIBITOR FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- - 12589 91000 37
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - -2-106
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - -
Assay Description Organism Bioactivity Reference
Compound was tested for the inhibition of HeLa DNA polymerase None 37.0 %
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Homo sapiens 100.0 ug.mL-1
Inhibition of DNA polymerase None 79.0 %
Inhibition of DNA polymerase None 40.0 %
Effective concentration required against HCMV AD169 for antiviral activity Human herpesvirus 5 16.0 ug.mL-1
Effective concentration required against HCMV strain for antiviral activity Human herpesvirus 5 16.0 ug.mL-1
Antiviral activity against herpes simplex virus-1 KOS in E6SM cell culture herpes simplex virus 0.015 ug.mL-1
Antiviral activity in herpes simplex virus-2 (HSV-2) G strain in E6SM cell culture hsv-2 0.02 ug.mL-1
Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines. Homo sapiens 3.4 ug.mL-1
Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates) Homo sapiens 5.4 ug.mL-1
Tested for inhibitory activity against Varicella zoster virus(VZV) by plaque reduction assay using HEL cells Homo sapiens 3.4 ug.mL-1
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain Homo sapiens 160.0 nM
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain Homo sapiens 780.0 nM
Inhibitory activity against DM625 strain of zoster virus(VZV) by plaque reduction assay in HFF cells None 2.7 ug.mL-1
Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells Homo sapiens 320.0 nM
Antiviral activity against thymidine kinase-negative (TK-) O7/1 strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Homo sapiens 22.0 ug.mL-1
Antiviral activity against thymidine kinase-negative (TK-) YS/R strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Homo sapiens 9.0 ug.mL-1
Antiviral activity against thymidine kinase-positive (TK+) OKA strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Homo sapiens 0.23 ug.mL-1
Antiviral activity against thymidine kinase-positive (TK+) YS strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Homo sapiens 0.32 ug.mL-1
Antiviral activity against cytomegalovirus (CMV) AD169 strain in HEL cell culture Human herpesvirus 5 13.0 ug.mL-1
Antiviral activity in TK+ varicella zoster virus (VZV) 07/1 strain in HEL cell culture Human herpesvirus 3 11.0 ug.mL-1
Antiviral activity in TK+ varicella zoster virus (VZV) OKA strain in HEL cell culture Human herpesvirus 3 0.18 ug.mL-1
Antiviral activity in TK+ varicella zoster virus (VZV) YS strain in HEL cell culture Human herpesvirus 3 0.35 ug.mL-1
Antiviral activity in TK+ varicella zoster virus (VZV) YS/R strain in HEL cell culture Human herpesvirus 3 22.0 ug.mL-1
Tested for inhibitory effect on DNA virus CMV (AD-169) in HEL cell line Homo sapiens 26.0 ug.mL-1
Tested for inhibitory effect on DNA virus CMV (Davis) in HEL cell line Homo sapiens 22.0 ug.mL-1
Tested for inhibitory effect on DNA virus TK-VZV (07/1) in HEL cell line Homo sapiens 4.0 ug.mL-1
Tested for inhibitory effect on DNA virus TK-VZV (YS/R) in HEL cell line Homo sapiens 5.0 ug.mL-1
Tested for inhibitory effect on DNA virus VZV (Oka) in HEL cell line Homo sapiens 0.1 ug.mL-1
Tested for inhibitory effect on DNA virus VZV (YS) in HEL cell line Homo sapiens 0.1 ug.mL-1
Tested for inhibitory effect on RNA virus cell growth in HEL cell line Homo sapiens 200.0 ug.mL-1
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. Homo sapiens 0.04 ug.mL-1
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% Homo sapiens 0.15 ug.mL-1
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. Homo sapiens 20.0 ug.mL-1
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. Homo sapiens 15.0 ug.mL-1
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. Homo sapiens 3.0 ug.mL-1
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. Homo sapiens 5.0 ug.mL-1
Antiviral activity was measured against Varicella-Zoster virus (VZV) 07/1 strain in human embryonic lung (HEL) cells Homo sapiens 24.0 ug.mL-1
Antiviral activity was measured against Varicella-Zoster virus (VZV) YS/R strain in human embryonic lung (HEL) cells Homo sapiens 26.0 ug.mL-1
Anti-VZV activity against 07/1 TK- in HEL cells Human herpesvirus 3 25.0 ug.mL-1
Anti-VZV activity against OKA strain TK+ in HEL cells Human herpesvirus 3 0.82 ug.mL-1
Anti-VZV activity against YS TK+ in HEL cells Human herpesvirus 3 0.95 ug.mL-1
Anti-VZV activity against YS/R TK- in HEL cells Human herpesvirus 3 40.0 ug.mL-1
In vitro inhibitory concentration for antiviral activity was tested against HEL cells Homo sapiens 50.0 ug.mL-1
Tested for antiviral activity against HSV-1 (KOS) Human herpesvirus 1 0.01 ug.mL-1
Tested for antiviral activity against HSV-1 (TK-KOS) Human herpesvirus 1 9.6 ug.mL-1
In Vitro antiviral activity against HSV-1 at 0.05 ug/mL concentration Human herpesvirus 1 100.0 %
In Vitro antiviral activity against HSV-1 at 0.5 ug/mL concentration Human herpesvirus 1 100.0 %
In Vitro antiviral activity against HSV-1 at 5 ug/mL concentration Human herpesvirus 1 100.0 %
In Vitro antiviral activity against HSV-1 at 50 ug/mL concentration Human herpesvirus 1 100.0 %
In Vitro antiviral activity against HSV-1 at 500 ug/mL concentration Human herpesvirus 1 100.0 %
In Vitro cytotoxicity against HSV-1 at 5 ug/mL concentration Human herpesvirus 1 0.0 %
In Vitro cytotoxicity against HSV-1 at 50 ug/mL concentration Human herpesvirus 1 0.0 %
In Vitro cytotoxicity against HSV-1 at 500 ug/mL concentration Human herpesvirus 1 0.0 %
Antiviral activity against herpes simplex virus-1. Human herpesvirus 1 200.0 nM
Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle Human herpesvirus 1 0.077 ug.mL-1
Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Human herpesvirus 1 0.077 ug.mL-1
Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Human herpesvirus 1 48.0 ug.mL-1
Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle Human herpesvirus 1 0.077 ug.mL-1
The compound was tested for the cytopathic effect inhibition against herpes simplex virus 2; Effective concentration required to inhibit 50% virus proliferation Human herpesvirus 2 0.2 ug.mL-1
The compound was tested for the viral plaque reduction against herpes simplex virus 2; Effective concentration required to inhibit 50% virus proliferation Human herpesvirus 2 1.1 ug.mL-1
Compound was evaluated for the antiviral activity against HSV-2 Human herpesvirus 2 5.12 ug.mL-1
Compound was tested for antiviral activity against HSV-2 Human herpesvirus 2 0.88 ug.mL-1
Tested for antiviral activity against HSV-2 (G) Human herpesvirus 2 0.02 ug.mL-1
Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle hsv-2 0.384 ug.mL-1
Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle hsv-2 0.384 ug.mL-1
Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle hsv-2 0.384 ug.mL-1
Compound was tested for the inhibition of HSV-1 polymerase Human herpesvirus 1 86.0 %
In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells Human herpesvirus 1 100.0 ug.mL-1
Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells Human herpesvirus 1 2.6 ug.mL-1
The compound was tested for plaque inhibition in HSV-1 in cell culture, activity is determined by plaque reduction assay Human herpesvirus 1 100.0 nM
The compound was tested for the cytopathic effect inhibition against herpes simplex virus 1; Effective concentration required to inhibit 50% virus proliferation Human herpesvirus 1 0.06 ug.mL-1 The compound was tested for the cytopathic effect inhibition against herpes simplex virus 1; Effective concentration required to inhibit 50% virus proliferation Human herpesvirus 1 0.3 ug.mL-1
Antiviral activity against HSV-1 (herpes simplex virus) Human herpesvirus 1 160.0 nM
Compound was evaluated for the antiviral activity against HSV-1 Human herpesvirus 1 1.054 ug.mL-1
Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture Homo sapiens 190.0 nM
Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (KOS) in HeLa cell culture Homo sapiens 110.0 nM
Antiviral activity against Herpes simplex virus type-1 (HSV-1). Human herpesvirus 1 360.0 nM
Compound was tested for antiviral activity against HSV-1 Human herpesvirus 1 0.13 ug.mL-1
In vitro antiviral activity was evaluated against HSV-1 using viral plaque reduction assay Human herpesvirus 1 400.0 nM
Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet. Homo sapiens 250.0 ug.mL-1
Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture. Homo sapiens 0.1 ug.mL-1
Inhibition of cytopathogenicity of herpes simplex type 2 virus(HSV-12(G) in Hela cell culture Homo sapiens 0.23 ug.mL-1
Inhibition of cytopathogenicity of Varicella-Zoster virus(VZV)(YS) in Hela cell culture. Homo sapiens 20.0 ug.mL-1
In vitro antiviral activity was evaluated against HSV-2 using viral plaque reduction assay Human herpesvirus 2 400.0 nM
Tested for inhibitory activity against Herpes simplex virus type-1(HSV-1), activity is expressed as IC50. herpes simplex virus 0.81 ug.mL-1
Evaluated for DNA polymerase inhibition activity against herpes simplex virus-1 (HSV-1) Human herpesvirus 1 85.0 %
Evaluated for DNA polymerase inhibition activity against HeLa cells. herpes simplex virus-2 34.0 %
Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells Homo sapiens 40.0 nM
Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells Homo sapiens 90.0 nM
Cytotoxicity against human neoplastic cell line(KB cells) Homo sapiens 100.0 %
Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines. Homo sapiens 0.29 ug.mL-1
Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines. Homo sapiens 0.25 ug.mL-1
Tested for Antiherpetic activity against VZV from clinical isolates of MRC-5 cell lines.(average of six isolates) Homo sapiens 1.3 ug.mL-1
Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line Homo sapiens 100.0 ug.mL-1
Concentration required to reduce HSV-1 (KOS strain) induced cytopathogenicity in NC-37 cells Homo sapiens 0.17 ug.mL-1
Ability (300 uM) to compete with 150 uM of [14C]ACV for binding sites on viral enzyme, Mac strain (HSV-1 TK) Human herpesvirus 1 69.0 %
Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells None 1.5 ug.mL-1
Inhibitory activity against Herpes Simplex virus type 1 (186 strain) in a Plaque reduction Assay in vero cells Chlorocebus sabaeus 0.5 ug.mL-1
Inhibitory activity against Herpes Simplex virus type 1 (KOS strain) in a Plaque reduction Assay in vero cells Chlorocebus sabaeus 0.1 ug.mL-1
Tested for antiviral activity against VZV (TK-KOS) Human herpesvirus 3 13.0 ug.mL-1
Tested for antiviral activity against VZV (YS) Human herpesvirus 3 1.1 ug.mL-1
The concentration required to reduce virus plaque formation by 50% was measured on 07/1 strain of VZV expressing viral thymidine kinase(TK-) Human herpesvirus 3 24.0 ug.mL-1
The concentration required to reduce virus plaque formation by 50% was measured on OKA strain of VZV expressing viral thymidine kinase(TK+) Human herpesvirus 3 0.73 ug.mL-1
The concentration required to reduce virus plaque formation by 50% was measured on YS strain of VZV expressing viral thymidine kinase(TK+) Human herpesvirus 3 0.78 ug.mL-1
The concentration required to reduce virus plaque formation by 50% was measured on YS/Rstrain of VZV expressing viral thymidine kinase(TK-) Human herpesvirus 3 26.0 ug.mL-1
Antiviral activity was tested against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50% Human herpesvirus 3 6.5 ug.mL-1
Antiviral activity was tested against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50% Human herpesvirus 3 0.35 ug.mL-1
Antiviral activity was tested against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50% Human herpesvirus 3 0.38 ug.mL-1
Antiviral activity was tested against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50% Human herpesvirus 3 3.1 ug.mL-1
The compound was tested for the cytopathic effect inhibition against herpes simplex virus 2; Effective concentration required to inhibit 50% virus proliferation Human herpesvirus 3 0.6 ug.mL-1
In vitro inhibitory concentration for antiviral activity was tested against vero cells Chlorocebus sabaeus 50.0 ug.mL-1
Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells Human herpesvirus 1 0.81 ug.mL-1
The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay Chlorocebus sabaeus 100.0 nM
Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells Chlorocebus sabaeus 0.5 ug.mL-1
Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells Chlorocebus sabaeus 40.0 ug.mL-1
In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in vero cells by a plaque reduction assay Chlorocebus sabaeus 0.32 ug.mL-1
In vitro evaluation of antiviral activity against HSV-2 (Herpes simplex virus-2) induced cytopathic effect in vero cells by a plaque reduction assay Chlorocebus sabaeus 0.39 ug.mL-1
Tested for antiviral activity against HBV (Hep AD79) Hepatitis B virus 50.0 ug.mL-1
Compound was evaluated for its cytotoxicity. None 250.0 ug.mL-1
Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle Vaccinia virus 400.0 ug.mL-1
Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle Vesicular stomatitis virus 400.0 ug.mL-1
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture Homo sapiens 0.38 ug.mL-1
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture Homo sapiens 0.07 ug.mL-1
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture Homo sapiens 0.07 ug.mL-1
Effective concentration to inhibit 50% of hepatitis B virus replication in a cell culture model Hepatitis B virus 20.0 nM
Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay herpes simplex virus 900.0 nM
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture Homo sapiens 48.0 ug.mL-1
Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells Human herpesvirus 1 320.0 nM
Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture Human herpesvirus 3 900.0 nM
Effective concentration of compound required to reduce plaque formation by OKA strain of thymidine kinase positive VZ virus TK+ in human embryonic lung cells Human herpesvirus 3 0.6 ug.mL-1
Reduction of plaque formation by VZV07/1 strain of thymidine kinase(TK-) deficient VZ virus in human embryonic lung cells Human herpesvirus 3 9.4 ug.mL-1
Effective concentration to reduce plaque formation of thymidine kinase positive Varicella zoster virus TK+ VZ OKA strain in human embryonic lung cell cultures Human herpesvirus 3 0.6 ug.mL-1
Effective concentration to reduce plaque formation of thymidine kinase deficient Varicella zoster virus TK- VZV 07/1 strain in human embryonic lung cell cultures Human herpesvirus 3 9.4 ug.mL-1
Antiviral activity against TK+ VZV OKA in human embryonic lung cells Human herpesvirus 3 0.22 ug.mL-1
Antiviral activity against TK- VZV 07/10 in human embryonic lung cells Human herpesvirus 3 14.0 ug.mL-1
Antiviral activity against HSV1 at 10 uM Human herpesvirus 1 96.0 %
Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA Human herpesvirus 4 330.0 nM
Inhibition of VZV replication in HFF cells by cytopathic effect assay Human herpesvirus 3 30.0 nM
Antiviral activity against HSV1 KOS in HEL cells Human herpesvirus 1 strain KOS 480.0 nM
Antiviral activity against HSV2 in HEL cells Human herpesvirus 2 480.0 nM
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 1 strain KOS 0.015 ug.mL-1
Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 1 strain KOS 20.0 ug.mL-1
Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 2 0.018 ug.mL-1
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 2 0.048 ug.mL-1
Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation Human herpesvirus 3 0.75 ug.mL-1
Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation Human herpesvirus 3 25.1 ug.mL-1
Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 0.02 ug.mL-1
Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 2 0.07 ug.mL-1
Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity Vaccinia virus 400.0 ug.mL-1
Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 1 40.0 ug.mL-1
Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 1 7.0 ug.mL-1
Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method Human herpesvirus 1 390.0 nM
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 0.03 ug.mL-1
Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 25.2 ug.mL-1
Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 2 0.02 ug.mL-1
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 2 0.05 ug.mL-1
Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 3 0.23 ug.mL-1
Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 3 10.2 ug.mL-1
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation Human herpesvirus 3 0.7 ug.mL-1
Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation Human herpesvirus 3 28.0 ug.mL-1
Antiviral activity against HSV1 SC16 in african green monkey Vero cells Human herpesvirus 1 390.0 nM
Antiviral activity against HSV1 Human herpesvirus 1 950.0 nM
Antiviral activity against HSV2 Human herpesvirus 2 950.0 nM
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs Human herpesvirus 2 strain G 200.0 nM
Antiviral activity against herpes simplex virus type 2 assessed as effect on virus-induced cytopathic effect Human herpesvirus 2 2.3 ug.mL-1
Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed inhibition of virus-induced effect after 48 hrs by MTT assay Human herpesvirus 2 4.21 ug.mL-1
Antiviral activity against HSV1 infected in african green monkey Vero cells after 72 hrs by SRB assay Human herpesvirus 1 2.0 ug.mL-1
Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Human herpesvirus 1 0.8 ug.mL-1
Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Human herpesvirus 2 2.4 ug.mL-1
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 4.8 ug.mL-1
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 12.0 ug.mL-1
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 7.9 ug.mL-1
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 173.0 ug.mL-1
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 130.0 ug.mL-1
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 91.0 ug.mL-1
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 7.7 ug.mL-1
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 22.0 ug.mL-1
Antiviral activity against HSV1 Human herpesvirus 1 0.24 ug.mL-1
Antiviral activity against HSV2 Human herpesvirus 2 0.22 ug.mL-1
Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect Human herpesvirus 1 0.25 ug.mL-1
Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect Influenza A virus 15.7 ug.mL-1
Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect Human coxsackievirus B3 25.0 ug.mL-1
Antiviral activity against HSV1 ATCC VR260 by colorimetry Human herpesvirus 1 0.5 ug.mL-1
Antiviral activity against HSV1 Human herpesvirus 1 1.1 ug.mL-1
Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation Human herpesvirus 3 0.17 ug.mL-1
Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation Human herpesvirus 3 16.0 ug.mL-1
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy Homo sapiens -3.9 %
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity Human herpesvirus 3 0.24 ug.mL-1
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity Human herpesvirus 3 13.0 ug.mL-1
Antiviral activity against Vaccinia virus Vaccinia virus 384.0 nM
Antiviral activity against HSV1 assessed as inhibition of virus-induced cytopathicity Human herpesvirus 1 0.18 ug.mL-1
Antiviral activity against HSV2 assessed as inhibition of virus-induced cytopathicity Human herpesvirus 2 0.36 ug.mL-1
Antiviral activity against HSV2 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Human herpesvirus 2 2.3 ug.mL-1
Antiviral activity against HSV1 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Human herpesvirus 1 0.26 ug.mL-1
Cytotoxicity against HSV1 infected human Hep2 cells after 3 days Homo sapiens 67.0 ug.mL-1
Cytotoxicity against HSV2 infected human Hep2 cells after 3 days Homo sapiens 10.0 ug.mL-1
Antiviral activity against HSV2 MS in african green monkey Vero cells by viral cytopathic effect assay Human herpesvirus 2 1.5 ug.mL-1
Cytotoxicity against african green monkey Vero cells by MTT assay Chlorocebus sabaeus 100.0 ug.mL-1
Antiviral activity against herpes simplex virus 1 infected in MDCK cells Human herpesvirus 1 0.1 ug.mL-1
Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay Human herpesvirus 1 580.0 nM
Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay Human herpesvirus 1 320.0 nM
Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay Human herpesvirus 1 300.0 nM
Antiviral activity against EHV1 assessed as inhibition of plaque formation Equid herpesvirus 1 1.7 ug.mL-1
Antiviral activity against HSV1 by green fluorescent protein microplate assay Human herpesvirus 1 6.86 ug.mL-1
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 2 strain G 200.0 nM
Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method Herpes simplex virus (type 1 / strain SC16) 390.0 nM
Antiviral activity against thymidine kinase expressing Varicella Zoster Virus OKA infected in HEL cells assessed as reduction of viral plaque formation Human herpesvirus 3 840.0 nM
Antiviral activity against HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity Human herpesvirus 1 strain KOS 160.0 nM
Antiviral activity against acyclovir-resistant HSV2 strain G infected in HEL assessed as reduction in virus-induce cytopathicity Human herpesvirus 2 strain G 300.0 nM
Antiviral activity against HSV1 E377 infected in HFF after 3 days by plaque reduction assay Human herpesvirus 1 80.0 nM
Antiviral activity against HSV1 PAA5 harboring polymerase R842S mutant gene infected in HFF after 3 days by plaque reduction assay Human herpesvirus 1 11.0 nM
Antiviral activity against HSV1 SC16-S1 harboring TK A265T/C336Y mutant gene infected in HFF after 3 days by plaque reduction assay Human herpesvirus 1 600.0 nM
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 2 strain G 200.0 nM
Antiviral activity against Herpes simplex viruses 1 infected in vero cells assessed as inhibition of viral replication at 50 uM after 72 hrs by XTT assay Human herpesvirus 1 95.0 %
Antiviral activity against 5 MOI Herpes simplex viruses 1 infected in vero cells after 24 hrs by viral plaque number reduction assay Human herpesvirus 1 990.0 nM
Antiviral activity against HSV1 by plaque reduction assay Human herpesvirus 1 300.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Human herpesvirus 2 strain G 400.0 nM
Antiviral activity against Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay Human herpesvirus 1 strain KOS 300.0 nM
Antiviral activity against Herpes simplex virus 2 strain G assessed as reduction of virus induced cytopathicity by cell based assay Human herpesvirus 2 strain G 230.0 nM
Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Human herpesvirus 1 strain KOS 270.0 nM
Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity Human herpesvirus 2 strain G 230.0 nM
Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay Human herpesvirus 1 strain KOS 600.0 nM
Antiherpetic activity against HSV2 at 0.5 mg/ml by MTT assay Human herpesvirus 2 66.3 %
Antiherpetic activity against HSV2 at 0.25 mg/ml by MTT assay Human herpesvirus 2 60.6 %
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Human herpesvirus 1 strain KOS 200.0 nM
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Human herpesvirus 2 strain G 400.0 nM
Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days Human herpesvirus 3 strain Oka vaccine 490.0 nM
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay Human herpesvirus 1 530.0 nM
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay Human herpesvirus 2 strain G 380.0 nM
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus yield at 20 ug/ml after 3 days by MTT assay Human herpesvirus 1 94.0 %
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 3 days by MTT assay Human herpesvirus 1 2.1 ug.mL-1
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay Human herpesvirus 1 1.6 ug.mL-1
Antiviral activity against HSV-2G ATCC 734 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay Human herpesvirus 2 strain G 1.8 ug.mL-1
Antiviral activity against HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against HSV2 G infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days Human herpesvirus 2 strain G 400.0 nM
Antiviral activity against Herpes simplex virus (type 1 / strain F) infected in Vero cells assessed as reduction of number of viral plaques after 2 days Herpes simplex virus (type 1 / strain F) 500.0 nM
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting Homo sapiens 2.3 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens -2.0 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens -15.2 %
Antiviral activity against HSV1 F ATCC VR733 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days Herpes simplex virus (type 1 / strain F) 0.2 ug.mL-1
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 2 strain G 140.0 nM
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 1 strain KOS 140.0 nM
Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.001 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method Human herpesvirus 1 760.0 nM
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 3 days by plaque reduction assay Human herpesvirus 1 1.5 ug.mL-1
Antiviral activity against Human herpesvirus 1 at 10 uM by end point titration assay Human herpesvirus 1 96.0 %
Antiviral activity against thymidine kinase-deficient Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation Human herpesvirus 3 23.0 ug.mL-1
Antiviral activity against thymidine kinase-positive Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation Human herpesvirus 3 0.44 ug.mL-1
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Human herpesvirus 2 strain G 700.0 nM
Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Human herpesvirus 2 strain G 80.0 nM
Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Human herpesvirus 1 strain KOS 80.0 nM
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Human herpesvirus 2 strain G 200.0 nM
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 200.0 nM
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 2 strain G 200.0 nM
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation Human herpesvirus 3 strain Oka vaccine 26.0 nM
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 103.39 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 105.48 %
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 2 strain G 500.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 1 strain KOS 320.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 2 strain G 200.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 1 strain KOS 230.0 nM
Antiviral activity against thymidine kinase-positive Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days Human herpesvirus 1 strain KOS 200.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days Human herpesvirus 2 strain G 100.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 200.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 2 strain G 80.0 nM
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay Herpes simplex virus (type 1 / strain F) 660.0 nM
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique Human herpesvirus 2 270.0 nM
Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis Human herpesvirus 1 strain KOS 70.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Human herpesvirus 1 strain KOS 80.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation Human herpesvirus 2 strain G 200.0 nM
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as reduction in virus plaque formation Human herpesvirus 3 strain Oka vaccine 800.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 200.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity Human herpesvirus 2 strain G 400.0 nM
Antiviral activity against Herpes simplex virus-1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Herpes simplex virus (type 1 / strain F) 410.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Human herpesvirus 1 strain KOS 200.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Human herpesvirus 2 100.0 nM
Antiviral activity against Human cytomegalovirus strain Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Human herpesvirus 5 510.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 2 strain G 400.0 nM
Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 1 strain KOS 400.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 2 strain G 180.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 1 strain KOS 800.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Human herpesvirus 2 strain G 400.0 nM
Antiviral activity against HSV1/F infected in African green monkey Vero cells assessed as inhibition of plaque formation after 24 hrs by crystal violet staining-based assay Human alphaherpesvirus 1 strain F 150.0 nM
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay Human herpesvirus 1 0.00475 nM
Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay Human herpesvirus 2 0.00311 nM
Antiviral activity against Human simplex virus 2 G infected in HEL cells assessed as reduction in viral cytopathic effect Human herpesvirus 2 strain G 700.0 nM
Antiviral activity against HSV1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Human alphaherpesvirus 1 strain F 410.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection Human herpesvirus 1 strain KOS 300.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection Human herpesvirus 2 strain G 290.0 nM
Antiviral activity against HSV1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days Human herpesvirus 1 strain KOS 380.0 nM
Antiviral activity against HSV2 strain G infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days Human herpesvirus 2 strain G 290.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection Human herpesvirus 1 strain KOS 470.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection Human herpesvirus 2 strain G 340.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method Human alphaherpesvirus 1 strain KOS 600.0 nM
Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method Human herpesvirus 2 strain G 600.0 nM
Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity Human herpesvirus 1 strain KOS 200.0 nM
Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity Human herpesvirus 2 strain G 200.0 nM
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus -22.02 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli 4.79 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 6.29 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa 9.14 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 6.13 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 4.6 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans -1.27 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 8.75 %
Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis Human alphaherpesvirus 1 900.0 nM
Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis Human alphaherpesvirus 2 900.0 nM
Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as reduction in virus-induced cytopathic effect incubated for 72 hrs by MTT assay Hepatitis A virus 35.6 ug.mL-1
Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral adsorption using cells pre-incubated with compound for 24 hrs before viral infection for 1 hr by MTT assay Hepatitis A virus 33.5 ug.mL-1
Antiviral activity against Hepatitis A virus infected in rhesus monkey FRhK4 cells assessed as inhibition in viral replication using cells pre-infected with virus before compound exposure for 72 hrs by MTT assay Hepatitis A virus 30.6 ug.mL-1
Antiviral activity against Herpes simplex virus 1 KOS infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis Human alphaherpesvirus 1 900.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 6.729 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.04 %
Inhibition of HSV2 replication in HFF cells incubated for 7 days Human alphaherpesvirus 2 990.0 nM
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus-induced cytopathogenic effect measured after 3 days coulter counter method Human alphaherpesvirus 3 490.0 nM
Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as reduction in virus titer preincubated for 24 hrs followed by viral infection and measured after 72 hrs by microscopic analysis Enterovirus E 222.0
Antiviral activity against Varicella zoster virus assessed as inhibition of viral replication Human alphaherpesvirus 3 9.0 nM

Related Entries

Environmental Exposure

Environmental Exposure Map
Countries
Germany
USA

Cross References

Resources Reference
ChEBI 2453
ChEMBL CHEMBL184
DrugBank DB00787
DrugCentral 85
FDA SRS X4HES1O11F
Human Metabolome Database HMDB0014925
Guide to Pharmacology 4829
KEGG C06810
PDB AC2
PharmGKB PA448045
PubChem 135398513
SureChEMBL SCHEMBL3175
ZINC ZINC000001530555
CONTENTS